Mahmoud Suleiman MD. On behalf of the Israeli ICD Registry Scientific Committee. Jan 11, National ICD Registry

Similar documents
Do All Patients With An ICD Indication Need A BiV Pacing Device?

PERFORMANCE MEASURE TECHNICAL SPECIFICATIONS. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate

Supplemental Material

NEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Tachycardia Devices Indications and Basic Trouble Shooting

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

Who does not need a primary preventive ICD?

Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure

Prophylactic ablation

The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia

Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM

Silvia G Priori MD PhD

עדכונים באלקטרופיזיולוגיה Electrophysiology Unit Soroka University Medical Center Faculty of Health Sciences Ben-Gurion University of the Negev

Device Update Implantable Cardioverter Defibrillator (ICD) 박상원

Risk Stratification of Sudden Cardiac Death

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012

The Role of ICD Therapy in Cardiac Resynchronization

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD

Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD

Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy

UnitedHealthcare Medicare Advantage Cardiology Prior Authorization Program

What You Should Know About Subcutaneous and Transvenous ICD

Synopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist

INNOVATIONS IN DEVICE THERAPY:

ICD THERAPIES: are they harmful or just high risk markers?

Defibrillation threshold testing should no longer be performed: contra

Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks

La gestione di un paziente con ICD: come evitare gli shock inappropriati e prolungare la sopravvivenza del paziente. Maurizio Gasparini

Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In?

MADIT-RIT: Simple programming change averts most inappropriate ICD therapy

THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA

Continuous ECG telemonitoring with implantable devices: the expected clinical benefits

New scientific documents from EHRA Management of patients with defibrillator shocks

ACD Heart failure - biventricular pacing (cardiac resynchronisation)

Προβληµατισµοί κατά την αντικατάσταση απινιδωτή. Νέος απινιδωτής, βηµατοδότης ή τίποτα;

ESC Stockholm Arrhythmias & pacing

DOWNLOAD OR READ : VALIDITY OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES IN ASSESSING DAILY PHYSICAL ACTIVITY PDF EBOOK EPUB MOBI

Preventing Sudden Death Current & Future Role of ICD Therapy

A Closer Look Product Education at a glance

Shock Reduction Strategies Michael Geist E. Wolfson MC

MEDICAL POLICY SUBJECT: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR

Newer pacemakers also can monitor your blood temperature, breathing, and other factors and adjust your heart rate to changes in your activity.

Supplementary Online Content

The Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years

Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.

Sudden death as co-morbidity in patients following vascular intervention

Cardiac Resynchronization Therapy. Michelle Khoo, MD

CRT-P or CRT-D From North Alberta to Nairobi

Hospital and Physician Reimbursement Guide for ICD Implants

Tech Corner. ATP in the Fast VT zone

InterQual Care Planning SIM plus Criteria 2014 Clinical Revisions

2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC

What Every Physician Should Know:

Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm

Need to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia

Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life

Arrhythmias Focused Review. Who Needs An ICD?

Subcutaneous Implantable Cardioverter Defibrillator (ICD) System

Chapter 4: Cardiovascular Disease in Patients With CKD

Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT

Implantable Cardioverter-Defibril. Defibrillators. Ratko Magjarević

UnitedHealthcare, UnitedHealthcare of the River Valley and Neighborhood Health Partnership Cardiology Notification and Prior Authorization Program:

Device Interrogation- Pacemakers, ICD and Loop Recorders. Dulce Obias-Manno, RN, MHSA, CCDS,CEPS, FHRS Device Clinic Coordinator, MHVI

Indications for catheter ablation in 2010: Ventricular Tachycardia

Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες

Dual-Chamber Implantable Cardioverter-Defibrillator

Policy #: 168 Latest Review Date: October 2014

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

ARRHYTHMIAS AND DEVICE THERAPY

ICD in a young patient with syncope

Large RCT s of CRT 2002 to present

SUPPLEMENTAL MATERIAL

Summary, conclusions and future perspectives

EHRA Accreditation Exam - Sample MCQs Cardiac Pacing and ICDs

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

The patient with electric storm

Heart Failure Challenges and Unmet needs

Implantable Cardioverter Defibrillator

Live Better Electrically

PACEMAKER INTERPRETATION AND DEVICE MANAGEMENT PART II

A Deep Dive: Using Device Diagnostics to Assist with Patient Management. Karen Donatello, RN, RCIS, CCDS

UnitedHealthcare, UnitedHealthcare of the River Valley and Neighborhood Health Partnership Cardiology Notification and Prior Authorization Program:

ICD Therapy. Disclaimers

Role of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death

Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis

Risk prediction in inherited conditions Laminopathies

ICD Diagnostics: Making the most of it

Implantable Cardioverter Defibrillator. Description

Original Policy Date

Chapter 4: Cardiovascular Disease in Patients With CKD

C h a p t e r 15. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias

Vest Prevention of Early Sudden Death Trial (VEST)

Sudden Cardiac Death and Asians Disclosures

Transcription:

The Israeli ICD Registry- Update Mahmoud Suleiman MD On behalf of the Israeli ICD Registry Scientific Committee Jan 11, 2013

Jul 2010-Dec 2012 Total Number of Procedures N=5280 New Implants N=3448 Generator Change N= 1278 Lead Related/other N=554 Primary = 74% Secondary= 26% Primary= 58% Secondary= 42% Lead only= 505 System removal 19 Pocket revision= 30

Reason(s) for ICD Implantation Primary Prevention Secondary Prevention High Risk Familial Disease 3% MADIT II /SCDHFT 74% Other 4% MADIT I /MUSTT 19% Syncope with Induced VT 7% Unknown etiology 5% Syncope with high Risk Features 10% VT 42% Other 1% VF 35%

Baseline Characteristics of New Implants variable All n= 2388 Primary n= 1743 Secondary n= 645 Age 64±13 64±15 64±12 0.86 Female 17 18 16 0.4 Old MI 64 65 63 0.3 < 40 days 8 6 13 <0.001 Non ischemic CM 22 25 14 <0.001 HCM 6 6 7 0.3 ARVD 0.6 0.3 1.5 0.001 Primary Electrical Disease 3 1.4 8 <0.001 Atrial Fibrillation 21 20 22 0.44 Diabetes Mellitus 36 38 31 0.003 Hypertension 60 61 56 0.04 Dialysis 2 2 2 0.9 Smoking 31 30 32 0.57 P

New Implants Device Type CRTD 39% Single 17% CRTD 39% Single 20% CRTD w plug 16% Dual 28% Dual 41%

Device Type and Gender ICD CRTD ICD CRTD 39 38 48 47 45 57 51 61 62 52 53 55 43 49 All Male Female Primary Male Female MADIT II

900 Trends of New Implants 800 700 600 500 400 671 768 615 700 694 487 590 445 517 512 2010 2011 2012 300 200 100 0 0 1 st half 2 nd half Total 0 1 st half 2 nd half Primary

Follow-up Studies

Completed Sub-studies 1. Sex Differences in Implantable Cardioverter Defibrillator Implantation Indications and Outcomes: Lessons from the Nation-wide Israeli-ICD Registry 2. Role of defibrillation threshold testing prior to ICD implantation 3. Renal Function and Clinical Outcomes of Patients Undergoing ICD or CRTD Implantation Guy Amit Moti Haim Moti Haim 4. Prognostic Value of Programmed Electrical Stimulation for Primary Prevention Implantable Cardioverter-Defibrillator Implantation 1. Outcomes of Patients who Received Appropriate shocks as 5. Clinical compared Characteristics to patients and who Outcomes received Inappropriate of Elderly Patients shock or no Treated shock with ICD and CRTD in a Real World Setting 6. Outcome of Patients with Advanced Heart Failure who Receive Device-Based Therapy for Primary Prevention of Sudden Cardiac Death JE. Schliamser M. Suleiman M. Suleiman

Suggested sub-studies 1. Outcomes of Patients who Received Appropriate Shocks as Compared to Patients who Received Inappropriate Shock or no Shock 2. Is Dual-Chamber ICDs Associated with Increased Long Mortality when Compared with Single-Chamber Defibrillators: a subanalysis of the Israeli ICD Registry? 3. Do Patients with End-Stage Kidney Disease Benefit from Prophylactic ICD Therapy? 4. 1. Syncope Outcomes Significance of Patients in who Patients Received Implanted Appropriate with ICDs shocks for as Primary Prevention compared of to Sudden patients Death who received Inappropriate shock or no shock 5. Development of Models for the 6 Months and one Year Mortality after ICD Implantation

Suggested sub-studies 6. Frequency of inappropriate shocks in patients with single vs dual chamber ICD 7. Rates of upgrade of plugged CRT-D device to full CRT in clinical practice and the potential clinical and economic impact of the use of plugged CRT-D device at initial implant 8. Impact of lead or pocked revision on clinical outcomes in patients with ICD/CRTD 9. 1. Prospective Outcomes Comparison of Patients who of Clinical Received Performance Appropriate shocks and Survival as of Different compared Transvenous to patients Defibrillation who received Leads Inappropriate shock or no shock 10. Atrial fibrillation (new, paroxysmal and chronic) and outcome in patients implanted with ICD/CRTD

Suggested sub-studies 11. Outcomes in CRTD Recipients with Atrial Fibrillation 12. Outcomes in ICD recipients who have pacemaker indications 13. Racial disparity in the utilization of implantable cardioverterdefibrillators and Cardiac resynchronization therapy among Israeli patients 14. Outcomes in ICD recipients with Genetic inherited arrhythmogenic disease in the real world settings

Clinical Characteristics and Outcomes of Elderly Patients Treated with Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy in a Real World Setting

Fig. 1A Total Population Event-free Survival Adj HR=1.66 (1.11-2.49) P=0.01 Adj HR= 2.25 (1.51-3.34) P<0.001

Fig. 1A Event-free Survival Adj HR=2.58 (1.47-4.51) P<0.001 Adj HR= 3.74 (2.14-6.53) P<0.001

Adj HR=1.01 (0.54-1.83) P=0.98 Event-free Survival Adj HR= 1.30 (0.72-2.33) P=0.38

Event-free Survival Adj HR=1.95 (1.24-3.07) P=0.003 Adj HR= 2.78 (1.80-4.31) P<0.001

Adj HR=1.01 (0.50-2.35) P=0.82 Adj HR=2.07 (1.02-4.20) P=0.04

Patient (%)

Major Findings >50% of new implants are in patients >65 yo and >20% in patients >75 yo Elderly patients have a higher risk profile and were more likely to receive CRTD device and have their device implanted for secondary prevention indication Elderly patients had a similar low re-intervention rate as younger patients. The risk of both HF and arrhythmic outcomes was attenuated among elderly patients implanted with CRT-D devices.

Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death

Cumulative probability of HF or Death Total Population Event-free survival Adj HR=1.01 (0.50-2.35) P=0.82

Cumulative probability of HF or death in ICD patients Event-free survival Adj HR=3.2 (1.7-6.3) p<0.001

Cumulative probability of HF or death in CRTD patients Event-free survival Adj HR=0.9 (0.5-1.8) p=0.92

Cumulative probability of death or appropriate device therapy for VT/VF

NYHA change during FU 90 80 78 % Patients 70 60 50 40 30 20 10 58 P<0.001 for the comparison between ICD and CRTD 17 8 4 38 ICD CRTD 0 No change Increased Decreased NYHA class change

Major Findings Patients with advanced HF who receive ICD for primary prevention of SCD are at increased risk of recurrent HF hospitalization High baseline NYHA class was not associated with recurrent HF hospitalization in patients implanted with CRTD Higher baseline NYHA was associated with reduced ventricular arrhythmias risk regardless of device type CRTD implantation was associated with higher rate of functional class improvement as compared to implantation of an ICD

תודות המשתתפים- המרכזים החברות נציגי רופאים, למחקרי לב וכלי דם העמותה גולדנברג אלין פרופ' ואורית נטלי,ליזי שלומית, וחברי הועד יו"ר המדעית והוועדה וטכנאים אחיות

The Israeli ICD Registry- Update Mahmoud Suleiman MD On behalf of the Israeli ICD Registry Scientific Committee Jan 11, 2013